Patents by Inventor Atsufumi Kawabata
Atsufumi Kawabata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220363667Abstract: To provide a novel T-type calcium channel blocker. A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker.Type: ApplicationFiled: July 17, 2019Publication date: November 17, 2022Inventors: Hiroto Tanaka, Isao Ooi, Daisuke Saito, Kohei Hayashida, Kohei Yamamoto, Atsufumi Kawabata
-
Patent number: 11479537Abstract: A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.Type: GrantFiled: September 21, 2018Date of Patent: October 25, 2022Assignees: KINKI UNIVERSITY, NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Atsufumi Kawabata, Fumiko Sekiguchi, Maho Tsubota, Naoki Toyooka, Hiroyuki Nishikawa
-
Patent number: 11420944Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a 5-membered heteroaryl group or a fused ring of a 5-membered or 6-membered heterocyclic ring with a benzene ring or a pyridine ring, each of which may have a substituent; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent, or the like; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2.Type: GrantFiled: January 12, 2017Date of Patent: August 23, 2022Assignees: Nippon Chemiphar Co., Ltd., Kinki UniversityInventors: Hiroto Tanaka, Isao Ooi, Yuzo Mogi, Masaaki Hirose, Tsuyoshi Endo, Toru Ogawa, Atsufumi Kawabata
-
Publication number: 20220226299Abstract: A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.Type: ApplicationFiled: March 26, 2020Publication date: July 21, 2022Applicants: NIPPON CHEMIPHAR CO., LTD., UTI LIMITED PARTNERSHIP, KINKI UNIVERSITYInventors: Gerald W. ZAMPONI, Vinicius de Maria GADOTTI, Atsufumi KAWABATA, Toru OGAWA, Hiroto TANAKA, Isao OOI, Daisuke SAITO, Kohei HAYASHIDA, Kohei YAMAMOTO
-
Patent number: 11370761Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydrType: GrantFiled: January 22, 2018Date of Patent: June 28, 2022Assignees: Nippon Chemiphar Co., Ltd., Kinki UniversityInventors: Hiroto Tanaka, Isao Ooi, Kohei Hayashida, Toru Ogawa, Atsufumi Kawabata
-
Publication number: 20210323930Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydrType: ApplicationFiled: January 22, 2018Publication date: October 21, 2021Inventors: Hiroto Tanaka, Isao Ooi, Kohei Hayashida, Toru Ogawa, Atsufumi Kawabata
-
Publication number: 20200308132Abstract: A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.Type: ApplicationFiled: September 21, 2018Publication date: October 1, 2020Inventors: Atsufumi KAWABATA, Fumiko SEKIGUCHI, Maho TSUBOTA, Naoki TOYOOKA, Hiroyuki NISHIKAWA
-
Patent number: 10709767Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.Type: GrantFiled: May 17, 2013Date of Patent: July 14, 2020Assignees: KINKI UNIVERSITY, ASAHI KASEI PHARMA CORPORATIONInventors: Atsufumi Kawabata, Hideaki Suzuki
-
Patent number: 10633358Abstract: The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action.Type: GrantFiled: November 8, 2017Date of Patent: April 28, 2020Assignees: KINKI UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Atsufumi Kawabata, Hideaki Matsuda, Fumiko Sekiguchi, Kazuya Murata, Hiroyuki Nishikawa
-
Publication number: 20190077767Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represType: ApplicationFiled: January 12, 2017Publication date: March 14, 2019Applicants: Nippon Chemiphar Co., Ltd., Kinki UniversityInventors: Hiroto TANAKA, Isao OOI, Yuzo MOGI, Masaaki HIROSE, Tsuyoshi ENDO, Toru OGAWA, Atsufumi KAWABATA
-
Publication number: 20180065947Abstract: The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action.Type: ApplicationFiled: November 8, 2017Publication date: March 8, 2018Inventors: Atsufumi KAWABATA, Hideaki MATSUDA, Fumiko SEKIGUCHI, Kazuya MURATA, Hiroyuki NISHIKAWA
-
Publication number: 20160096815Abstract: The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action.Type: ApplicationFiled: May 16, 2014Publication date: April 7, 2016Inventors: Atsufumi KAWABATA, Hideaki MATSUDA, Fumiko SEKIGUCHI, Kazuya MURATA, Hiroyuki NISHIKAWA
-
Publication number: 20150148296Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.Type: ApplicationFiled: May 17, 2013Publication date: May 28, 2015Applicants: ASAHI KASEI PHARMA CORPORATION, KINKI UNIVERSITYInventors: Atsufumi Kawabata, Hideaki Suzuki
-
Patent number: 8383595Abstract: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition for promoting lacrimal secretion comprising a peptide derivative represented by the formula (I): and a contact lens which retains and/or contains the composition are provided.Type: GrantFiled: June 15, 2009Date of Patent: February 26, 2013Assignees: Kinki University, Fuso Pharmaceutical Industries, Ltd.Inventors: Atsufumi Kawabata, Hiroyuki Nishikawa, Yoshiko Kawai
-
Publication number: 20110224154Abstract: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition for promoting lacrimal secretion comprising a peptide derivative represented by the formula (I): and a contact lens which retains and/or contains the composition are provided.Type: ApplicationFiled: June 19, 2009Publication date: September 15, 2011Applicants: KINKI UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Atsufumi Kawabata, Hiroyuki Nishikawa, Kenzo Kawai, Yoshiko Kawai
-
Patent number: 7550437Abstract: The present invention provides a composition for safely and effectively preventing and treating digestive organs diseases, particularly, gastric ulcer, duodenal ulcer, gastritis, diarrhea, enteritis and the like. There is also provided a composition having a novel mechanism of action in order to solve the problems which was difficult to be solved by the side effect previously known mechanisms of action. More particularly, there is provided a pharmaceutical composition containing an ingredient which activates PAR-2 as an essential ingredient, which is useful for inhibiting gastric acid secretion, promoting digestive tract mucus secretion, protecting digestive tract mucosa, repairing tissue of digestive organs, and preventing and treating digestive organs diseases.Type: GrantFiled: January 3, 2006Date of Patent: June 23, 2009Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Hiromasa Araki, Atsufumi Kawabata, Ryotaro Kuroda, Kazuaki Kakehi, Shuichi Tanaka, Kenzo Kawai, Sachiyo Nishimura, Hiroyuki Nishikawa
-
Patent number: 7348306Abstract: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition comprises a component which activates PAR-2. Also, a contact lens which retains and/or contains said composition for promoting lacrimal secretion is provided.Type: GrantFiled: August 26, 2005Date of Patent: March 25, 2008Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Hiromasa Araki, Atsufumi Kawabata, Shuichi Tanaka, Kenzo Kawai, Hiroyuki Nishikawa, Sachiyo Nishimura
-
Publication number: 20060172949Abstract: The present invention provides a composition for safely and effectively preventing and treating digestive organs diseases, particularly, gastric ulcer, duodenal ulcer, gastritis, diarrhea, enteritis and the like. There is also provided a composition having a novel mechanism of action in order to solve the problems which was difficult to be solved by the side effect previously known mechanisms of action. More particularly, there is provided a pharmaceutical composition containing an ingredient which activates PAR-2 as an essential ingredient, which is useful for inhibiting gastric acid secretion, promoting digestive tract mucus secretion, protecting digestive tract mucosa, repairing tissue of digestive organs, and preventing and treating digestive organs diseases.Type: ApplicationFiled: January 3, 2006Publication date: August 3, 2006Applicant: FUSO PHARMACEUTICAL IND. LTD.Inventors: Hiromasa Araki, Atsufumi Kawabata, Ryotaro Kuroda, Kazuaki Kakehi, Shuichi Tanaka, Kenzo Kawai, Sachiyo Nishimura, Hiroyuki Nishikawa
-
Publication number: 20060019904Abstract: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition comprises a component which activates PAR-2. Also, a contact lens which retains and/or contains said composition for promoting lacrimal secretion is provided.Type: ApplicationFiled: August 26, 2005Publication date: January 26, 2006Applicant: FUSO Pharmaceutical Industries, Ltd.Inventors: Hiromasa Araki, Atsufumi Kawabata, Shuichi Tanaka, Kenzo Kawai, Sachiyo Nishimura, Hiroyuki Nishikawa
-
Publication number: 20030203849Abstract: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition comprises a component which activates PAR-2. Also, a contact lens which retains and/or contains said composition for promoting lacrimal secretion is provided.Type: ApplicationFiled: June 27, 2002Publication date: October 30, 2003Inventors: Hiromasa Araki, Atsufumi Kawabata, Shuichi Tanaka, Kenzo Kawai, Sachiyo Nishimura, Hiroyuki Nishikawa